Bone cell-independent benefits of raloxifene on the skeleton: A novel mechanism for improving bone material properties

Bone

Volumn 61, Issue , 2014, Pages 191-200

  Gallant, Maxime A ^a   Brown, Drew M ^a   Hammond, Max ^b   Wallace, Joseph M ^c   Du, Jiang ^d   Deymier Black, Alix C ^e   Almer, Jonathan D ^f   Stock, Stuart R ^g   Allen, Matthew R ^a   Burr, David B ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Indiana University Purdue University Indianapolis   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Northwestern University   (United States)

^f ARGONNE NATIONAL LABORATORY   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Mechanical testing; Raloxifene; Toughness; Water

Indexed keywords

MECHANICAL TESTING; RALOXIFENE; TOUGHNESS; WATER;

ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DOGS; EXTRACELLULAR MATRIX; HUMANS; RALOXIFENE; SKELETON;

EID: 84893810527     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.01.009     Document Type: Article

References (37)

1. Felsenberg D., Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005, 27:1-11.
2. Baron R., Ferrari S., Russell R.G.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
3. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
4. Bryant H.U. Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulator*. Rev Endocr Metab Disord 2001, 2:129-138.
5. Gallagher J.C., Levine J.P. Preventing osteoporosis in symptomatic postmenopausal women. Menopause 2011, 18:109-118.
6. Reginster J.-Y. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011, 71:65-78.
7. Allen M.R., Hogan H.A., Hobbs W.A., Koivuniemi A.S., Koivuniemi M.C., Burr D.B. Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology 2007, 148:3908-3913.
8. Allen M.R., Iwata K., Sato M., Burr D.B. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 2006, 39:1130-1135.
9. Diab T., Wang J., Reienwald S., Guldberg R.E., Burr D.B. Effects of the combination treatment 1 of raloxifene and alendronate on the biomechanical properties of vertebral bone. J Bone Miner Res 2010, 26:270-276.
10. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999, 140:5828-5840.
11. Mann V., Huber C., Kogianni G., Collins F., Noble B. The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007, 40:674-684.
12. Arteaga E., Villaseca P., Bianchi M., Rojas A., Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 2003, 10:142-146.
13. Yu J., Eto M., Kozaki K., Akishita M., Okabe T., Ouchi Y. Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway. Eur J Pharmacol 2008, 589:32-36.
14. Blasbichler M., Arakil-Aghajanian A., Sinzinger H. Raloxifene does not prevent fibrinogen oxidation in vitro. Med Sci Monit 2005, 11:PI1.
15. Krum S.A., Miranda-Carboni G.A., Hauschka P.V., Carroll J.S., Lane T.F., Freedman L.P., et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008, 27:535-545.
16. Grese T.A., Cho S., Finley D.R., Godfrey A.G., Jones C.D., Lugar C.W., et al. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 1997, 40:146-167.
17. 2-induced rat endothelial cell apoptosis. Am J Physiol Endocrinol Metab 2007, 292:E585-E593.
18. Horch R.A., Gochberg D.F., Nyman J.S., Does M.D. Clinically compatible MRI strategies for discriminating bound and pore water in cortical bone. Magn Reson Med 2012, 68:1774-1784.
19. Du J., Bydder M., Takahashi A.M., Carl M., Chung C.B., Bydder G.M. Short T2 contrast with three-dimensional ultrashort echo time imaging. Magn Reson Imaging 2011, 29:470-482.
20. Du J., Carl M., Bydder M., Takahashi A., Chung C.B., Bydder G.M. Qualitative and quantitative ultrashort echo time (UTE) imaging of cortical bone. J Magn Reson 2010, 207:304-311.
21. Techawiboonwong A., Song H.K., Leonard M.B., Wehrli F.W. Cortical bone water: in vivo quantification with ultrashort echo-time MR Imaging1. Radiology 2008, 248:824-833.
22. Du J., Hamilton G., Takahashi A., Bydder M., Chung C.B. Ultrashort echo time spectroscopic imaging (UTESI) of cortical bone. Magn Reson Med 2007, 58:1001-1009.
23. Kemp D.C., Fan P.W., Stevens J.C. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 2002, 30:694-700.
24. Almer J., Stock S. Micromechanical response of mineral and collagen phases in bone. J Struct Biol 2007, 157:365-370.
25. Cattani-Lorente M., Rizzoli R., Ammann P. In vitro exposure to strontium improves bone material level properties. Acta Biomater 2013, 9:7005-7013.
26. Anumula S., Wehrli S.L., Magland J., Wright A.C., Wehrli F.W. Ultra-short echo-time MRI detects changes in bone mineralization and water content in OVX rat bone in response to alendronate treatment. Bone 2010, 46:1391-1399.
27. Luo Q., Nakade R., Dong X., Rong Q., Wang X. Effect of mineral-collagen interfacial behavior on the microdamage progression in bone using a probabilistic cohesive finite element model. J Mech Behav Biomed Mater 2011, 4:943-952.
28. Wallace J.M., Erickson B., Les C.M., Orr B.G., Banaszak Holl M.M. Distribution of type I collagen morphologies in bone: relation to estrogen depletion. Bone 2010, 46:1349-1354.
29. Wallace J.M., Orr B.G., Marini J.C., Holl M.M.B. Nanoscale morphology of Type I collagen is altered in the Brtl mouse model of Osteogenesis Imperfecta. J Struct Biol 2011, 173:146-152.
30. Yan J., Daga A., Kumar R., Mecholsky J.J. Fracture toughness and work of fracture of hydrated, dehydrated, and ashed bovine bone. J Biomech 2008, 41:1929-1936.
31. Nyman J.S., Roy A., Shen X., Acuna R.L., Tyler J.H., Wang X. The influence of water removal on the strength and toughness of cortical bone. J Biomech 2006, 39:931-938.
32. Nyman J.S., Ni Q., Nicolella D.P., Wang X. Measurements of mobile and bound water by nuclear magnetic resonance correlate with mechanical properties of bone. Bone 2008, 42:193-199.
33. Wang X., Shen X., Li X., Mauli Agrawal C. Age-related changes in the collagen network and toughness of bone. Bone 2002, 31:1-7.
34. Zioupos P., Currey J. Changes in the stiffness, strength, and toughness of human cortical bone with age. Bone 1998, 22:57-66.
35. Bae W.C., Chen P.C., Chung C.B., Masuda K., D'Lima D., Du J. Quantitative ultrashort echo time (UTE) MRI of human cortical bone: correlation with porosity and biomechanical properties. J Bone Miner Res 2012, 27:848-857.
36. 1H NMR compared with high resolution X-ray. PLoS One 2011, 6:e16359.
37. Jacobsen D.E., Samson M.M., Emmelot-Vonk M.H., Verhaar H.J. Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol 2010, 162:371-376.